As of 14 Oct 2026, Pathos has raised $365M across 1 verified round on record; latest: $365 million Series D, announced 15 May 2025.
Pathos integrates AI technology, biological modeling, and the largest collection of oncology patient data to make clinical trials smarter and more precise.
pathos.comLinkedInBostonBiotech
1 source
The article says the round included returning backers and new investors, but none were identified. New Enterprise Associates is named only as the lead of Pathos’s earlier Series C.
Published by hand (fiercebiotech.com): "Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of solid tumor drugs sourced from Novo Nordisk and Prelude Therapeutics.": biggest-rounds completeness (K): hand-checked, the cited page states $365 million
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series D [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $365M at $1.6 billion valuation | 2025-05-15 | not stated | No recent discussion |
1 source [ VERIFIED ] read against 1 source
The article says the round included returning backers and new investors, but none were identified. New Enterprise Associates is named only as the lead of Pathos’s earlier Series C. Published by hand (fiercebiotech.com): "Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of solid tumor drugs sourced from Novo Nordisk and Prelude Therapeutics.": biggest-rounds completeness (K): hand-checked, the cited page states $365 million | ||||
None named.